Literature DB >> 19369270

Enhanced heterogeneity of rpoB in Mycobacterium tuberculosis found at low pH.

Claire Jenkins1, Joanna Bacon, Jon Allnutt, Kim A Hatch, Alpana Bose, Denise M O'Sullivan, Catherine Arnold, Stephen H Gillespie, Timothy D McHugh.   

Abstract

OBJECTIVES: The aim of this study was to gain an insight into the molecular mechanisms of the evolution of rifampicin resistance in response to controlled changes in the environment.
METHODS: We determined the proportion of rpoB mutants in the chemostat culture and characterized the sequence of mutations found in the rifampicin resistance-determining region of rpoB in a steady-state chemostat at pH 7.0 and 6.2.
RESULTS: The overall proportion of rpoB mutants of strain H37Rv remained constant for 37 days at pH 7.0, ranging between 3.6 x 10(-8) and 8.9 x 10(-8); however, the spectrum of mutations varied. The most commonly detected mutation, serine to leucine mutation at codon 531 (S531L), increased from 40% to 89%, while other mutations (S531W, H526Y, H526D, H526R, S522L and D516V) decreased over the 37 day sampling period. Changing the pH from 7.0 to 6.2 did not significantly alter the overall proportion of mutants, but resulted in a decrease in the percentage of strains harbouring S531L (from 89% to 50%) accompanied by an increase in the range of different mutations from 4 to 12.
CONCLUSIONS: The data confirm that the fitness of strains with the S531L mutation is greater than that of strains containing other mutations. We also conclude that at low pH the environment is permissive for a wider spectrum of mutations, which may provide opportunities for a successful mutant to survive.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19369270     DOI: 10.1093/jac/dkp125

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

Review 1.  Translating basic science insight into public health action for multidrug- and extensively drug-resistant tuberculosis.

Authors:  Nicholas D Walter; Michael Strong; Robert Belknap; Diane J Ordway; Charles L Daley; Edward D Chan
Journal:  Respirology       Date:  2012-07       Impact factor: 6.424

2.  Dynamic population changes in Mycobacterium tuberculosis during acquisition and fixation of drug resistance in patients.

Authors:  Gang Sun; Tao Luo; Chongguang Yang; Xinran Dong; Jing Li; Yongqiang Zhu; Huajun Zheng; Weidong Tian; Shengyue Wang; Clifton E Barry; Jian Mei; Qian Gao
Journal:  J Infect Dis       Date:  2012-09-14       Impact factor: 5.226

3.  Pre-existing isoniazid resistance, but not the genotype of Mycobacterium tuberculosis drives rifampicin resistance codon preference in vitro.

Authors:  Indra Bergval; Brian Kwok; Anja Schuitema; Kristin Kremer; Dick van Soolingen; Paul Klatser; Richard Anthony
Journal:  PLoS One       Date:  2012-01-03       Impact factor: 3.240

Review 4.  The impact of drug resistance on Mycobacterium tuberculosis physiology: what can we learn from rifampicin?

Authors:  Anastasia Koch; Valerie Mizrahi; Digby F Warner
Journal:  Emerg Microbes Infect       Date:  2014-03-12       Impact factor: 7.163

5.  Alterations in the Spectrum of Spontaneous Rifampicin-Resistance Mutations in the Bacillus subtilis rpoB Gene after Cultivation in the Human Spaceflight Environment.

Authors:  Patricia Fajardo-Cavazos; Joshua D Leehan; Wayne L Nicholson
Journal:  Front Microbiol       Date:  2018-02-14       Impact factor: 5.640

6.  Interaction between rpsL and gyrA mutations affects the fitness and dual resistance of Mycobacterium tuberculosis clinical isolates against streptomycin and fluoroquinolones.

Authors:  Honghu Sun; Jumei Zeng; Song Li; Pengkuan Liang; Chao Zheng; Yong Liu; Tao Luo; Nalin Rastogi; Qun Sun
Journal:  Infect Drug Resist       Date:  2018-03-27       Impact factor: 4.003

7.  Mycobacterium tuberculosis Is Resistant to Isoniazid at a Slow Growth Rate by Single Nucleotide Polymorphisms in katG Codon Ser315.

Authors:  Rose E Jeeves; Alice A N Marriott; Steven T Pullan; Kim A Hatch; Jon C Allnutt; Irene Freire-Martin; Charlotte L Hendon-Dunn; Robert Watson; Adam A Witney; Richard H Tyler; Catherine Arnold; Philip D Marsh; Timothy D McHugh; Joanna Bacon
Journal:  PLoS One       Date:  2015-09-18       Impact factor: 3.240

8.  The effect of growth rate on pyrazinamide activity in Mycobacterium tuberculosis - insights for early bactericidal activity?

Authors:  Steven T Pullan; Jon C Allnutt; Rebecca Devine; Kim A Hatch; Rose E Jeeves; Charlotte L Hendon-Dunn; Philip D Marsh; Joanna Bacon
Journal:  BMC Infect Dis       Date:  2016-05-17       Impact factor: 3.090

Review 9.  Molecular Targets Related Drug Resistance Mechanisms in MDR-, XDR-, and TDR-Mycobacterium tuberculosis Strains.

Authors:  H M Adnan Hameed; Md Mahmudul Islam; Chiranjibi Chhotaray; Changwei Wang; Yang Liu; Yaoju Tan; Xinjie Li; Shouyong Tan; Vincent Delorme; Wing W Yew; Jianxiong Liu; Tianyu Zhang
Journal:  Front Cell Infect Microbiol       Date:  2018-04-10       Impact factor: 5.293

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.